Inhaled corticosteroids and Aspergillus fumigatus isolation in cystic fibrosis

Medical Mycology

Volumn 52, Issue 7, 2014, Pages 715-722

  Noni, Maria ^a   Katelari, Anna ^a   Dimopoulos, George ^b   Kourlaba, Georgia ^a   Spoulou, Vana ^c   Athanassoulis, Helen Alexandrou ^c   Doudounakis, Stavros Eleftherios ^a   Bakoula, Chryssa Tzoumaka ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Aspergillus fumigatus; Cystic fibrosis; inhaled corticosteroids

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZITHROMYCIN; CORTICOSTEROID; DORNASE ALFA; IMMUNOSUPPRESSIVE AGENT;

ANTIBIOTIC THERAPY; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; COHORT ANALYSIS; CORTICOSTEROID THERAPY; CYSTIC FIBROSIS; FEMALE; FUNGAL COLONIZATION; FUNGUS CULTURE; FUNGUS ISOLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; REVIEW; TREATMENT DURATION; ADOLESCENT; ADULT; COMPLICATION; HETEROZYGOTE; INHALATIONAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; PULMONARY ASPERGILLOSIS; STATISTICAL MODEL; TIME FACTOR; YOUNG ADULT;

ASPERGILLUS FUMIGATUS;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ASPERGILLUS FUMIGATUS; CARRIER STATE; COHORT STUDIES; CYSTIC FIBROSIS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MODELS, STATISTICAL; PULMONARY ASPERGILLOSIS; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84911414183     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1093/mmy/myu038     Document Type: Review

References (43)

1. Cystic Fibrosis Foundation Patient Registry. Annual Data Report 2012. http://www.cff.org/UploadedFiles/research/ClinicalResearch/PatientRegistryReport/2012-CFF-Patient-Registry.pdf.
2. Robinson M, Bye PT. Mucociliary clearance in cystic fibrosis. Pediatr Pulmonol 2002; 33: 293-306.
3. Foweraker J. Recent advances in the microbiology of respiratory tract infection in cystic fibrosis. Br Med Bull 2009; 89: 93-110.
4. Whittaker LA, Teneback C. Atypical mycobacterial and fungal infections in cystic fibrosis. Semin Respir Crit Care Med 2009; 30: 539-546.
5. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110: 685-692.
6. Valenza G, Tappe D, Turnwald D et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros 2008; 7: 123-127.
7. Skov M, McKay K, Koch C et al. Prevalence of allergic bron-chopulmonary aspergillosis in cystic fibrosis in an area with a high frequency of atopy. Respir Med 2005; 99: 887-893.
8. Moss RB. Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis. Curr Opin Pulm Med 2010; 16: 598-603.
9. Dimopoulos G, Frantzeskaki F, Poulakou G et al. Invasive aspergillosis in the intensive care unit. Ann N Y Acad Sci 2012; 1272: 31-39.
10. Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. Eur Respir Rev 2011; 20: 156-174.
11. Liu JC, Modha DE, Gaillard EA. What is the clinical significance of filamentous fungi positive sputum cultures in patients with cystic fibrosis? J Cyst Fibros 2013; 12: 187-193.
12. Amin R, Dupuis A, Aaron SD et al. The effect of chronic infection with Aspergillus fumigatus on lung function and hospi-talization in patients with cystic fibrosis. Chest 2010; 137: 171-176.
13. de Vrankrijker AM, van der Ent CK, van Berkhout FT et al. Aspergillus fumigatus colonization in cystic fibrosis: implications for lung function? Clin Microbiol Infect 2011; 17: 1381-1386.
14. Bakare N, Rickerts V, Bargon J et al. Prevalence of Aspergillus fumigatus and other fungal species in the sputum of adult patients with cystic fibrosis. Mycoses 2003; 46: 19-23.
15. Konstan MW, Schluchter MD, Xue W et al. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007; 176: 1084-1089.
16. Balfour-Lynn IM, Lees B, Hall P et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 2006; 173: 1356-1362.
17. Flume PA, O'Sullivan BP, Robinson KA et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176: 957-969.
18. Stevens DA, Moss RB, Kurup VP et al. Allergic bronchopul-monary aspergillosis in cystic fibrosis-state of the art: Cystic Fi-brosis Foundation Consensus Conference. Clin Infect Dis 2003; 37(Suppl 3): S225-264.
19. Laguna TA, Nathan BM, Moran A. Managing diabetes in cystic fibrosis. Diabetes Obes Metab 2010; 12: 858-864.
20. Lee TW et al. Evaluation of a new definition for chronic Pseu-domonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003; 2: 29-34.
21. UK Standards for Microbiology Investigations. Investigation of bronchoalveolar lavage, sputum and associated specimens. Bacteriology, B57, 2012.
22. Jubin V, Ranque S, Stremler Le Bel N et al. Risk factors for Aspergillus colonization and allergic bronchopulmonary as-pergillosis in children with cystic fibrosis. Pediatr Pulmonol 2010; 45: 764-771.
23. Ross KR, Chmiel JF, Konstan MW. The role of inhaled corti-costeroids in the management of cystic fibrosis. Paediatr Drugs 2009; 11: 101-113.
24. Cheng K, Ashby D, Smyth RL. Oral steroids for long-term use in cystic fibrosis. Cochrane Database Syst Rev 2011; 10: CD000407.
25. de Benedictis FM, Bush A. Corticosteroids in respiratory diseases in children. Am J Respir Crit Care Med 2012; 185: 12-23.
26. Nichols D, Chmiel J, Berger M. Chronic inflammation in the cystic fibrosis lung: alterations in inter-and intracellular signaling. Clin Rev Allergy Immunol 2008; 34: 146-162.
27. De Boeck K, De Baets F, Malfroot A et al. Do inhaled corticos-teroids impair long-term growth in prepubertal cystic fibrosis patients? Eur J Pediatr 2007; 166: 23-28.
28. Ren CL, Pasta DJ, Rasouliyan L et al. Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr 2008; 153: 746-751.
29. Minicucci L, Severi G, Cresta L et al. Impact of inhaled corticos-teroids on the risk of early Pseudomonas aeruginosa acquisition in cystic fibrosis. Acta Paediatr 2003; 92: 684-687.
30. Balfour-Lynn IM, Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev 2012; 11: CD001915.
31. Jensen T, Pedersen SS, Garne S et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aerug-inosa lung infection. J Antimicrob Chemother 1987; 19: 831-838.
32. Burns JL, Van Dalfsen JM, Shawar RM et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999; 179: 1190-1196.
33. Bargon J, Dauletbaev N, Kohler B et al. Prophylactic antibiotic therapy is associated with an increased prevalence of Aspergillus colonization in adult cystic fibrosis patients. Respir Med 1999; 93: 835-838.
34. Baxter CG, Rautemaa R, Jones AM et al. Intravenous antibiotics reduce the presence of Aspergillus in adult cystic fibrosis sputum. Thorax 2013; 68: 652-657.
35. Paugam A, Baixench M-T, Demazes-Dufeu N et al. Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Med Mycol 2010; 48(Suppl. 1): S32-S36.
36. Sudfeld CR, Dasenbrook EC, Merz WG et al. Prevalence and risk factors for recovery of filamentous fungi in individuals with cystic fibrosis. J Cyst Fibros 2010; 9: 110-116.
37. Mowat E, Rajendran R, Williams C et al. Pseudomonas aerug-inosa and their small diffusible extracellular molecules inhibit Aspergillus fumigatus biofilm formation. FEMS Microbiol Lett 2010; 313: 96-102.
38. Schultz MJ. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2004; 54: 21-28.
39. Svirshchevskaya E, Zubkov D, Mouyna I et al. Innate immunity and the role of epithelial barrier during Aspergillus fumigatus infection. Curr Immunol Rev 2012; 8: 254-261.
40. Jones AP, Wallis CE. Recombinant human deoxyribonucle-ase for cystic fibrosis. Cochrane Database Syst Rev 2003; 3: CD001127.
41. Konstan MW, Ratjen F. Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. J Cyst Fibros 2012; 11: 78-83.
42. Paul K, Rietschel E, Ballmann M et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004; 169: 719-725.
43. Jain K, Wainwright C, Smyth AR. Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. Cochrane Database Syst Rev 2013; 12: CD009530.